COVID-19 vaccines are very effective in reducing the severity of symptoms of the disease but do not prevent the virus from gaining a foothold in the nose
It reproduces stealthily in the nose and is thrown with coughing and sneezing, infecting others
All available vaccines provide antibodies and immunity in the blood, but the antibodies do not reach the nasal mucosa
Question: If the COVID-19 vaccine is sprayed into the nose, can it stimulate an immune response in the nasal mucosa and thus prevent the virus from spreading?
Promising animal experiments
It was found that viral loads are similar in the noses of vaccinated and unvaccinated individuals, and therefore the vaccinated should not remove their masks in closed spaces because they spread the virus to others.
Covid-19 vaccines are still in the first stage of their trials
Besides preventing transmission, potential advantages of intranasal vaccines over injected vaccines include ease of administration, possibly even self-administration.
Intranasal insemination is likely to be a welcome option for people with needle phobia
Both intranasal and injected vaccines produced high levels of systemic antibodies in hamsters
The Munster team also gave two doses of the nasal vaccine to four rhesus monkeys, which resulted in levels of antibodies similar to those observed in people who had recovered from COVID-19.
The vaccinated monkeys had fewer viruses in their nose and lung tissue than the unvaccinated monkeys.
Now Oxford University researchers are conducting an intranasal trial of the AstraZeneca vaccine in healthy human volunteers.
One concern about intranasal vaccines is that they can lead to respiratory disease, so the trial excludes people with lung disease, asthma and other respiratory illnesses.
In the future, a combination of the two vaccines may be seen, and the intranasal vaccine is used for primary immunization, followed by a booster dose of the injected vaccines.
On the other hand:
What looks promising in animals doesn't always work in people
According to a Maryland-based vaccine manufacturer, the nasal vaccine did not stimulate an adequate immune response in a trial of 80 people.
The vaccine appears to be well tolerated, but the magnitude of the immune response and the proportion of participants who responded were much lower than seen with injected COVID-19 vaccines.
So far: The company's intranasal vaccine does not meet expectations because the participants in the trial lack immunity to infection
One expert said: Based on the circulating antibodies, the intranasal vaccine will always look inferior.
All available vaccines provide antibodies and immunity in the blood, but the antibodies do not reach the nasal mucosa
Question: If the COVID-19 vaccine is sprayed into the nose, can it stimulate an immune response in the nasal mucosa and thus prevent the virus from spreading?
Promising animal experiments
It was found that viral loads are similar in the noses of vaccinated and unvaccinated individuals, and therefore the vaccinated should not remove their masks in closed spaces because they spread the virus to others.
Covid-19 vaccines are still in the first stage of their trials
Besides preventing transmission, potential advantages of intranasal vaccines over injected vaccines include ease of administration, possibly even self-administration.
Intranasal insemination is likely to be a welcome option for people with needle phobia
Both intranasal and injected vaccines produced high levels of systemic antibodies in hamsters
The Munster team also gave two doses of the nasal vaccine to four rhesus monkeys, which resulted in levels of antibodies similar to those observed in people who had recovered from COVID-19.
The vaccinated monkeys had fewer viruses in their nose and lung tissue than the unvaccinated monkeys.
Now Oxford University researchers are conducting an intranasal trial of the AstraZeneca vaccine in healthy human volunteers.
One concern about intranasal vaccines is that they can lead to respiratory disease, so the trial excludes people with lung disease, asthma and other respiratory illnesses.
In the future, a combination of the two vaccines may be seen, and the intranasal vaccine is used for primary immunization, followed by a booster dose of the injected vaccines.
On the other hand:
What looks promising in animals doesn't always work in people
According to a Maryland-based vaccine manufacturer, the nasal vaccine did not stimulate an adequate immune response in a trial of 80 people.
The vaccine appears to be well tolerated, but the magnitude of the immune response and the proportion of participants who responded were much lower than seen with injected COVID-19 vaccines.
So far: The company's intranasal vaccine does not meet expectations because the participants in the trial lack immunity to infection
One expert said: Based on the circulating antibodies, the intranasal vaccine will always look inferior.